Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate the prophylactic efficacy of REGN1908-1909 (anti-Fel d 1) administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat in the prevention of a Controlled Cat Allergen Challenge-induced early asthmatic response (EAR) assessed by measures of lung function (FEV1) compared to placebo-treated patients. Secondary Efficacy Objectives: - To evaluate the prophylactic efficacy of REGN1908-1909 administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat, in the prevention of a Controlled Cat Allergen Challenge-induced: Allergic rhinitis and Ocular symptoms - To evaluate the prophylactic efficacy of REGN1908-1909 administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat to increase the exposure to cat allergen, measured as a product of minute ventilation and time, required to induce EAR in a Controlled Cat Allergen Challenge as compared to placebo patients Secondary Safety Objective: - To evaluate the safety and tolerability of REGN1908-1909 vs. placebo in patients with cat allergen-triggered asthma


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03838731
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date February 12, 2019
Completion date April 6, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02959073 - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients N/A
Completed NCT00987909 - Exposure Chamber Trial With Cat Immunotherapy Phase 2
Completed NCT01383603 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis Phase 1
Completed NCT01383590 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis Phase 1
Completed NCT01003301 - The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Phase 2
Completed NCT02311413 - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy Phase 2
Completed NCT02237196 - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Phase 1/Phase 2
Completed NCT02399579 - Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients N/A
Terminated NCT01292070 - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy Phase 0
Completed NCT00867906 - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma Phase 2
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01033344 - Cat-PAD Exposure Chamber Study Phase 2
Completed NCT00685711 - Safety of Cat-PAD in Cat Allergic Subjects Phase 1/Phase 2
Completed NCT02040844 - Phase III Cat-PAD Follow-on Study Phase 3
Completed NCT01604018 - An Optional Two Year Follow Up Study to Study CP005A N/A
Completed NCT01272323 - Cat-PAD Follow on Study N/A
Completed NCT00729508 - Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects Phase 2
Recruiting NCT05331170 - Viral Mucosal Reprogramming Phase 2